1Fujie A;Iwamoto T;Muramatsu H.FR901469,a novel antifongal antibiotic from an unidentified fungus No.11243.Ⅱ.In vitro and in vivo activities,2000(09).
2Huang W;Na L;Fidel PL.Requirement of interleukin17A for systemic anti-Candida albicans host defense in mice,2004(03).
3Chretien F;Lortholary O;Kansau I.Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia,2002(04).
4Barchiesi F;Schimizzi AM;Najvar LK.Interactions of posaconazole and flucytosine against Cryptococcus neoformans[J],2001(05).
5Cacciapuoti A;Loebenberg D;Corcoran E.In vitro and in vivo activities of SCH 56592 (posaconazole),a new triazole antifungal agent,against Aspergillus and Candida[J],2000(08).
6Santangelo R;Zoellner H;Sorrell T.Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model[J],2004(04).
7Ashman RB;Papadimitriou JM.Production and function of cytokines in natural and acquired immunity to Candida albicans infection,1995(04).
8Habicht JM;Preiss M;Passweg J.Invasive pulmonary aspergillosis:effects of early resection in a neutropenic rat model[J],2002(05).
9Tissi L;Puliti M;Bistoni F.Glucuronoxylomannan,the major capsular polysaccharide of Cryptococcus neoformans,inhibits the progression of group B streptococcal arthritis[J],2004(11).
10Polonelli L;Casadevall A;Han Y.The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections[J],2000(z1).
